88IV - PR Newswire Asia's news - Medical/Pharmaceuticals

< Previous page

| Title only | Print

Next page >

Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart Disease NEW YORK , Aug. 24, 2026 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), today announced the enrollment of the ... 2026-08-24T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics SEONGNAM, South Korea , Aug. 24, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining ... 2026-08-24T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D SHANGHAI and HONG KONG , Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" , SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated ... 2026-08-24T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion TAIPEI , Aug. 24, 2026 /PRNewswire/ -- Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that ... 2026-08-24T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation SHANGHAI , Aug. 21, 2026 /PRNewswire/ -- On August 21, Henlius (2696.HK) announced its interim results for the 2026 fiscal year. During the reporting period, the company showcased strong organic ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Coreline Soft and INFINITT North America Deploy Chest CT-Based AI Reading Workflow at St. Joseph's Health PHILLIPSBURG, N.J. and ATLANTA , Aug. 21, 2026 /PRNewswire/ -- Coreline Soft, a leading medical AI innovator, and INFINITT North America have announced the deployment of a chest CT-based ... 2026-08-21T Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist SHANGHAI , Aug. 21, 2026 /PRNewswire/ -- CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"? BEIJING , Aug. 21, 2026 /PRNewswire/ -- Personalized mRNA cancer therapy has recently reached an important milestone. An international Phase 3 study in high-risk melanoma reported positive results, ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy NANJING, China , Aug. 21, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026 SHANGHAI , Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved